Nuclear medicine firm Curium has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for its copper-64 (Cu-64) PSMA I&T diagnostic radiopharmaceutical.
Designed to detect and localize metastatic prostate cancer on PET exams, Cu-64 PSMA I&T binds to prostate-specific membrane antigen (PSMA), according to the vendor. The radiopharmaceutical would enable imaging sites in the U.S. to provide PSMA-based prostate cancer imaging without local cyclotron production or access to a nearby gallium generator, Curium said.
